97 related articles for article (PubMed ID: 9137818)
1. Mutation of Arg154 to Gly154 in urokinase augments its fibrin-specificity.
Peng G; Ma Z; Kuai L; Zhu D
Biochem Mol Biol Int; 1997 Apr; 41(5):887-94. PubMed ID: 9137818
[TBL] [Abstract][Full Text] [Related]
2. Construction of Urokinase Mutant Glu154-mtcu-PA and Characterization of Its Properties.
Peng GH; Ma Z; Xue YM; Chen YH; Zhu DX
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 1997; 29(6):547-552. PubMed ID: 12215767
[TBL] [Abstract][Full Text] [Related]
3. Urokinase mutant with better fibrin-specificity.
Ma Z; Yu R; Hua Z; Zhu D
Sci China C Life Sci; 1996 Oct; 39(5):523-33. PubMed ID: 9772355
[TBL] [Abstract][Full Text] [Related]
4. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
Declerck PJ; Lijnen HR; Verstreken M; Moreau H; Collen D
Blood; 1990 May; 75(9):1794-800. PubMed ID: 1691934
[TBL] [Abstract][Full Text] [Related]
5. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
Holvoet P; Laroche Y; Lijnen HR; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
Eur J Biochem; 1992 Dec; 210(3):945-52. PubMed ID: 1483477
[TBL] [Abstract][Full Text] [Related]
6. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.
Dewerchin M; Lijnen HR; Van Hoef B; De Cock F; Collen D
Eur J Biochem; 1989 Oct; 185(1):141-9. PubMed ID: 2530085
[TBL] [Abstract][Full Text] [Related]
7. Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.
Lijnen HR; Li XK; Nelles L; Hu MH; Collen D
Eur J Biochem; 1992 Apr; 205(2):701-9. PubMed ID: 1533368
[TBL] [Abstract][Full Text] [Related]
8. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro.
Lijnen HR; Van Hoef B; De Cock F; Collen D
Blood; 1989 May; 73(7):1864-72. PubMed ID: 2713507
[TBL] [Abstract][Full Text] [Related]
9. Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158.
Nelles L; Lijnen HR; Collen D; Holmes WE
J Biol Chem; 1987 Apr; 262(12):5682-9. PubMed ID: 3106341
[TBL] [Abstract][Full Text] [Related]
10. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
Lijnen HR; Dewerchin M; De Cock F; Collen D
Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu).
Lijnen HR; Van Hoef B; Nelles L; Collen D
J Biol Chem; 1990 Mar; 265(9):5232-6. PubMed ID: 1969415
[TBL] [Abstract][Full Text] [Related]
12. Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.
Lijnen HR; Wnendt S; Schneider J; Janocha E; Van Hoef B; Collen D; Steffens GJ
Eur J Biochem; 1995 Nov; 234(1):350-7. PubMed ID: 8529664
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp130 and Ser139 of urokinase-type plasminogen activator.
Lijnen HR; Piérard L; Reff ME; Gheysen D
Thromb Res; 1988 Dec; 52(5):431-41. PubMed ID: 3146822
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
Nelles L; Lijnen HR; Collen D; Holmes WE
J Biol Chem; 1987 Aug; 262(22):10855-62. PubMed ID: 2956260
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis.
Fleury V; Lijnen HR; Anglés-Cano E
J Biol Chem; 1993 Sep; 268(25):18554-9. PubMed ID: 8103046
[TBL] [Abstract][Full Text] [Related]
16. Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.
Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
Eur J Biochem; 1988 Nov; 177(3):575-82. PubMed ID: 2973984
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
Lijnen HR; De Cock F; Collen D
Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
[TBL] [Abstract][Full Text] [Related]
18. Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
Li XK; Lijnen HR; Nelles L; Hu MH; Collen D
Biochim Biophys Acta; 1992 Sep; 1159(1):37-43. PubMed ID: 1390910
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
[TBL] [Abstract][Full Text] [Related]
20. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
